Amp Volatility Score
Catalyst Info & Data Links
TITLE: Losmapimod for COVID-19 - Phase 2
ClinicalTrial.gov (NCT04511819): Losmapimod Safety and Efficacy in COVID-19 (LOSVID)
WHAT IS THE NEXT CATALYST EVENT?
Update on Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds.
Updated by JM
FULC, Fulcrum Therapeutics, Losmapimod, COVID-19, Corona
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post